An Integrated Safety and Efficacy Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin

Reported by Jules Levin

AASLD 2014 Boston Nov 8-11

Marc Bourlière1, Mark Sulkowski2, Masao Omata3, Stefan Zeuzem4, Jordan Feld5, Eric Lawitz6, Patrick Marcellin7, Robert Hyland8, Xiao Ding8, Jenny Yang8, Steven Knox8, Phillip Pang8, Mani Subramanian8, William Symonds8, John McHutchison8, Alessandra Mangia9, Edward Gane10, K. Rajender Reddy11, Masashi Mizokami12, Stanislas Pol13, Nezam Afdhal14 1Hôpital Saint Joseph, Marseilles, France; 2Johns Hopkins University, Baltimore, MD; 3Yamanashi Prefectural Hospital Organization, Yamanashi, Japan; 4Johann Wolfgang Goethe University, Frankfurt am Main, Germany; 5Sandra Rotman Centre for Global Health, University of Toronto, Ontario, Canada; 6Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 7Hôpital Beaujon, University of Paris, France; 8Gilead Sciences, Inc., Foster City, CA; 9Liver Unit, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy; 10New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 11University of Pennsylvania, Philadelphia, PA; 12Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba, Japan; 13Department of Hepatology, Université Paris-René Descartes, France; 14Beth Israel Deaconess Medical Center, Boston, MA